Friday, July 31, 2015

Yaupon hires Ception's Tullman as new CEO

Yaupon Therapeutics Inc., of Radnor, has named Steve Tullman, the former chief executive of Ception Therapeutics, as its chairman and CEO.

Yaupon hires Ception's Tullman as new CEO

0 comments

Yaupon Therapeutics Inc., of Radnor, has named Steve Tullman, the former chief executive of Ception Therapeutics, as its chairman and CEO.

Yaupon's lead product is an experimental treatment for cutaneous T-cell lymphoma. The mechlorethamine gel has been granted "fast-track" status as well as "orphan drug" status by the Food and Drug Administration.

The company said in a statement that it expects to file a New Drug Application with the FDA for the product in mid-2011.

To do so, Tullman said in the statement that he would "build an experienced management team," including bringing in former Ception executives. Ception was acquired by Cephalon Inc. in April 2010.

Founded in 2002, Yaupon raised funds from BioAdvance and Ben Franklin Technology Partners of Southeastern Pennsylvania early on its in development.  It raised $14.5 million in 2007 from investors including Vivo Ventures and Palo Alto Investors L.L.C.

Tullman succeeds Robert Alonzo, one of the founders of Yaupon.

Inquirer Columnist
0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
Mike Armstrong blogs about Philadelphia corporations and business-related topics. Contact him at 215-854-2980. Reach Mike at marmstrong@phillynews.com.

Mike Armstrong Inquirer Columnist
Also on Philly.com:
letter icon Newsletter